IMMUNE DEFICIENCY

If you or a loved one has an IMMUNE DEFICIENCY, you might qualify for a trial and receive a new, investigational product at no cost. 

Research is at the heart of advancing our knowledge of IMMUNE DEFICIENCIES
Without people like you, we would not be where we are today.  
About the study

The purpose of this study is to assess efficacy and safety of Kedrion Immunoglobulin 10% (KIg10) in participants with Primary Immunodeficiency (PID).

Participants will receive intravenous infusion of Kedrion IVIG 10% at a dose of 200 to 800 milligram per kilogram (mg/kg) body weight every 21 or 28 days for period of 48 weeks.

To learn more about the study and see if you qualify, call today. 

614.430.3030

CLINICAL RESEARCH

For Yourself  |  For Future Generations

COVID-19

Due to COVID-19 outbreak - learn more about what we are doing to help

Our Story

Optimed Research was founded by Donald McNeil, MD in 1999 as a stand alone research site focused on Allergy and Immunology. Overtime, we have grown to a network of affiliated sites all over the country. Our focus now is helping, often naive, physicians conduct research. We use advanced cloud-based technology to help manage every aspect of a trial. This strategic relationship allows the Investigator to focus on providing the clinical oversight, while we in turn can focus on the administrative and regulatory responsibilities. Together we are able to provide better oversight while reducing the cost and burden research can have on a practice.  

8080 RAVINES EDGE COURT STE 200  COLUMBUS, OHIO 43235 |  
P: 614.430.3030  |  F: 614.430.8025  |  RESEARCH@OPTIMED.US.COM